Cargando…
Persistence and viability of SARS-CoV-2 in primary infection and reinfections
Since the beginning of the SARS-CoV-2 epidemic, virus isolation in the infected patient was only possible for a short period of time and it was striking that this occurred constantly and did not provide guidance on the clinical course. This fact led to confusion about the efficacy of some of the dru...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790642/ https://www.ncbi.nlm.nih.gov/pubmed/34661382 http://dx.doi.org/10.37201/req/129.2021 |
_version_ | 1784640061527031808 |
---|---|
author | Ruiz-Galiana, Julián Ramos, Pilar De Lucas García-Botella, Alejandra García-Lledó, Alberto Gómez-Pavón, Javier del Castillo, Juan González Teresa Hernández, Sampelayo Martín-Delgado, Mari Cruz Sánchez, Francisco Javier Martín Martínez-Sellés, Manuel García, José María Molero Guillén, Santiago Moreno Fernando Rodríguez, Artalejo Cantón, Rafael Bouza, Emilio |
author_facet | Ruiz-Galiana, Julián Ramos, Pilar De Lucas García-Botella, Alejandra García-Lledó, Alberto Gómez-Pavón, Javier del Castillo, Juan González Teresa Hernández, Sampelayo Martín-Delgado, Mari Cruz Sánchez, Francisco Javier Martín Martínez-Sellés, Manuel García, José María Molero Guillén, Santiago Moreno Fernando Rodríguez, Artalejo Cantón, Rafael Bouza, Emilio |
author_sort | Ruiz-Galiana, Julián |
collection | PubMed |
description | Since the beginning of the SARS-CoV-2 epidemic, virus isolation in the infected patient was only possible for a short period of time and it was striking that this occurred constantly and did not provide guidance on the clinical course. This fact led to confusion about the efficacy of some of the drugs initially used, which seemed to have a high efficiency in viral clearance and proved ineffective in modifying the course of the disease. The immune response also did not prove to be definitive in terms of evolution, although most of the patients with very mild disease had a weak or no antibody response, and the opposite was true for the most severe patients. With whatever the antibody response, few cases have been re-infected after a first infection and generally, those that have, have not reproduced a spectrum of disease similar to the first infection. Among those re-infected, a large number have been asymptomatic or with very few symptoms, others have had a moderate picture and very few have had a poor evolution. Despite this dynamic of rapid viral clearance, laboratory tests were still able to generate positive results in the recovery of genomic sequences and this occurred in patients who were already symptom-free, in others who were still ill and in those who were very seriously ill. There was also no good correlate. For this reason and with the perspective of this year and the half of pandemic, we compiled what the literature leaves us in these aspects and anticipating that, as always in biology, there are cases that jump the limits of the general behavior of the dynamics of infection in general. |
format | Online Article Text |
id | pubmed-8790642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Sociedad Española de Quimioterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-87906422022-02-07 Persistence and viability of SARS-CoV-2 in primary infection and reinfections Ruiz-Galiana, Julián Ramos, Pilar De Lucas García-Botella, Alejandra García-Lledó, Alberto Gómez-Pavón, Javier del Castillo, Juan González Teresa Hernández, Sampelayo Martín-Delgado, Mari Cruz Sánchez, Francisco Javier Martín Martínez-Sellés, Manuel García, José María Molero Guillén, Santiago Moreno Fernando Rodríguez, Artalejo Cantón, Rafael Bouza, Emilio Rev Esp Quimioter Review Since the beginning of the SARS-CoV-2 epidemic, virus isolation in the infected patient was only possible for a short period of time and it was striking that this occurred constantly and did not provide guidance on the clinical course. This fact led to confusion about the efficacy of some of the drugs initially used, which seemed to have a high efficiency in viral clearance and proved ineffective in modifying the course of the disease. The immune response also did not prove to be definitive in terms of evolution, although most of the patients with very mild disease had a weak or no antibody response, and the opposite was true for the most severe patients. With whatever the antibody response, few cases have been re-infected after a first infection and generally, those that have, have not reproduced a spectrum of disease similar to the first infection. Among those re-infected, a large number have been asymptomatic or with very few symptoms, others have had a moderate picture and very few have had a poor evolution. Despite this dynamic of rapid viral clearance, laboratory tests were still able to generate positive results in the recovery of genomic sequences and this occurred in patients who were already symptom-free, in others who were still ill and in those who were very seriously ill. There was also no good correlate. For this reason and with the perspective of this year and the half of pandemic, we compiled what the literature leaves us in these aspects and anticipating that, as always in biology, there are cases that jump the limits of the general behavior of the dynamics of infection in general. Sociedad Española de Quimioterapia 2021-10-18 2022 /pmc/articles/PMC8790642/ /pubmed/34661382 http://dx.doi.org/10.37201/req/129.2021 Text en © The Author 2021 https://creativecommons.org/licenses/by-nc/4.0/Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
spellingShingle | Review Ruiz-Galiana, Julián Ramos, Pilar De Lucas García-Botella, Alejandra García-Lledó, Alberto Gómez-Pavón, Javier del Castillo, Juan González Teresa Hernández, Sampelayo Martín-Delgado, Mari Cruz Sánchez, Francisco Javier Martín Martínez-Sellés, Manuel García, José María Molero Guillén, Santiago Moreno Fernando Rodríguez, Artalejo Cantón, Rafael Bouza, Emilio Persistence and viability of SARS-CoV-2 in primary infection and reinfections |
title | Persistence and viability of SARS-CoV-2 in primary infection and reinfections |
title_full | Persistence and viability of SARS-CoV-2 in primary infection and reinfections |
title_fullStr | Persistence and viability of SARS-CoV-2 in primary infection and reinfections |
title_full_unstemmed | Persistence and viability of SARS-CoV-2 in primary infection and reinfections |
title_short | Persistence and viability of SARS-CoV-2 in primary infection and reinfections |
title_sort | persistence and viability of sars-cov-2 in primary infection and reinfections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790642/ https://www.ncbi.nlm.nih.gov/pubmed/34661382 http://dx.doi.org/10.37201/req/129.2021 |
work_keys_str_mv | AT ruizgalianajulian persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT ramospilardelucas persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT garciabotellaalejandra persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT garcialledoalberto persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT gomezpavonjavier persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT delcastillojuangonzalez persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT teresahernandezsampelayo persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT martindelgadomaricruz persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT sanchezfranciscojaviermartin persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT martinezsellesmanuel persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT garciajosemariamolero persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT guillensantiagomoreno persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT fernandorodriguezartalejo persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT cantonrafael persistenceandviabilityofsarscov2inprimaryinfectionandreinfections AT bouzaemilio persistenceandviabilityofsarscov2inprimaryinfectionandreinfections |